PPARG and metabolic dysfunction-associated steatotic liver disease: Conversely, PPARγ induction by rosiglitazone decreases the number of hepatic Kupffer cells, attenuating the inflammatory response as well as steatosis in a diet-induced mouse model of NAFLD [133].